Synthego Presents at the 7th Annual CAR-TCR Summit

REDWOOD CITY, Calif. - Synthego, the genome engineering company, today announced that Rebecca Nugent, Ph.D., vice president of platform research at Synthego, will be presenting during the 7th Annual CAR-TCR Summit taking place in Boston from September 19-22, 2022. The CAR-TCR Summit is the world’s pre-eminent industry-leading comprehensive forum focused on advancing safe, effective and commercially viable CAR and TCR therapies from discovery to commercialization

In the presentation titled, "From Discovery to Clinic: Accelerating the Path from Discovery to a Developed Cell and Gene Therapy Product," Dr. Nugent focuses on an industrialized approach to CRISPR research and accelerating cell and gene therapy development. The approach employs multiplexing both gene editing efficiency and accuracy simultaneously leading to faster paths to de-risk biology and bespoke gene editing strategies in clinically relevant cells. The presentation will take place on September 20, 2022 at 11:45am EST.

Leveraging the company’s expertise in CRISPR and its leading platforms, Halo and Eclipse, Synthego can accelerate discovery for nuclease-based medicines and deliver unprecedented scale and quality to fuel research at any stage. With the recent investment in a new next-generation good manufacturing practices (GMP) factory, an expansion of the Halo platform, the company will significantly expand production of its precision gene editing tools and be well positioned to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.